Peptides Explained: The FDA Already Has a List of the Ones in Those Videos
The two biggest peptide videos in YouTube search right now have about 25 million views between them: “Peptides Are Insane,” posted twelve days ago, and “Exposing The Truth About Peptides,” posted a month ago. That is roughly 25 million people watching someone explain a category of molecule that a large share of them will be offered, injected or sold inside a year.
The honest version of peptides explained fits in one sentence. A peptide is a short chain of amino acids, and the word names a chemistry, not a benefit. The videos skip the paper trail. The FDA has already reviewed the specific peptides sold to consumers, compound by compound, and published what it knows about each one. That page is free, and it is more useful than any video on the subject.
Peptide – a chemistry word doing a sales job
Peptides are chains of amino acids, the building blocks of proteins. Insulin is a peptide hormone 51 amino acids long. GLP-1, the hormone the weight-loss drugs imitate, is a peptide. Semaglutide and tirzepatide are peptides with FDA approvals and trials behind them, which is the half of the word the videos celebrate.
The other half is the same word on a vial of BPC-157 stamped “not for human consumption.” Chemistry does not separate those two products. A label does, and so does a list. For the plain-language definition, see our page on what peptides are and what they cannot do.
The three doors – and the peptides standing outside all of them
Compounding law sets three doors into a vial. FDA’s own page lists them: a pharmacy or physician compounding under section 503A may use a bulk substance that complies with a United States Pharmacopeia or National Formulary monograph, or is a component of an FDA-approved drug, or appears on the 503A bulks list. A February 2019 final rule put six substances on that list.
The peptide menu fails all three tests, and the FDA has said so in writing to a named company. In a warning letter dated April 1, 2020, the agency told Tailor Made Compounding that it had compounded products using “Follistatin, GHRP-2, GHRP-6, Endurobal, AOD 9604, BPC 157, Bremelanotide (PT-141), Cerebrolysin, DSIP, Epitalon, GHK-Cu, IGF1-LR3, Ipamorelin, LL-37, Melanotan II, PEG-MGF, Selank, Semax, CJC 1295, SARMS, LGD-4033, and MK 677.” Those products, the letter states, are not eligible for the exemptions in section 503A because they are not the subject of a monograph, are not a component of an FDA-approved human drug, and do not appear on the 503A bulks list.
Read that list twice. It is the same menu selling in 2026, and it was already named in a federal enforcement letter six years ago.
BPC-157 – the FDA’s own sentence about harm
BPC-157 is the headliner of the category, and the FDA has written down why. Its safety page states that compounded drugs containing BPC-157 “may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization.” Then the sentence that decides the argument: the agency “has identified no, or only limited, safety-related information for the proposed routes of administration” and “lacks sufficient information to know whether the drug would cause harm when administered to humans.”
That is a regulator saying it does not know what happens to a person. A clinic selling vials of it is selling that sentence.
BPC-157 went further than most. The FDA’s Pharmacy Compounding Advisory Committee reviewed it in July 2026, and a committee vote is not a rule. Our own review of what that vote did and did not do explains why the regulation at 21 CFR 216.23 was not amended by it.
CJC-1295 and ipamorelin – the two lines a clinic menu will not print
Two growth-hormone peptides share a page in the FDA’s own risk table, and both entries are worse than a warning label.
For CJC-1295, the agency states it has “identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction,” and adds that available clinical data are limited.
For ipamorelin acetate, the FDA cites published work reporting “serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility.” Ipamorelin acetate also carries unnatural amino acids, which the agency notes make the peptide harder to characterize. Both compounds sit on the FDA’s list of substances that were previously placed in category 2, the category for substances that may present significant safety risks.
TB-500 and KPV – no human exposure data at all
The wolverine stack and the glow protocol rest on two peptides with the same gap in the record.
On thymosin beta-4 fragment, the compound marketed as TB-500, the FDA states it “has not identified any human exposure data drug products containing Thymosin Beta-4, Fragment,” and lacks important information on whether the drug would cause harm.
On KPV, the agency states it “has not identified any human exposure data on drug products containing KPV administered via any route of administration.”
No human exposure data means the dosing chart circulating on a forum was written by no trial. Both compounds were on the agenda at the July 2026 advisory meeting, which is the only reason a reader hears about them from a regulator at all.
GHK-Cu – the one question still open, and its date
Copper peptide GHK-Cu is the rare case where the answer is still open rather than settled. The FDA removed GHK-Cu from category 1 on April 22, 2026 after nominators withdrew, then one nominator clarified on May 5, 2026 that it had withdrawn only the injectable route and wanted to keep the rest. GHK-Cu for non-injectable routes went back to category 1, the list of substances under evaluation. The agency has said it intends to consult its advisory committee “before the end of February 2027” on whether GHK-Cu belongs on the 503A bulks list.
Pending is not approved. It is a date on a calendar, and until it passes the injectable form is in the same position as the rest of the menu. Our review of the skin and hair claims behind the same peptide covers how thin the human evidence runs.
The vial label – the sentence the FDA has thrown out before
One defense appears on peptide storefronts in small print: “research purposes only.” The FDA addressed it directly in a warning letter to Prime Vitality, doing business as Prime Peptides in Santa Barbara, dated December 10, 2024. The agency had reviewed the site selling products “as peptides” including semaglutide and retatrutide and found them to be unapproved new drugs under sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act.
The line worth memorizing: “Despite statements on your product labeling marketing your products for ‘research purposes only’ and ‘not for human consumption or clinical use,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.”
The lesson generalizes. A label cannot make a drug not a drug, and a seller’s own marketing copy is the evidence that closes the case. The same reasoning applies to the retatrutide vials moving now, which is the subject of our report on the trial numbers and the counterfeit problem in that market.
What to ask instead of asking what peptides are
Peptides explained is the wrong question, because the answer changes per compound. The question that sorts a clinic in five minutes is narrower: name the exact ingredient, then ask which of the three doors it came through.
- Ask for the compound name, the milligram amount and the pharmacy that produced the vial.
- Ask whether the product is FDA-approved or compounded. A compounded answer comes with a pharmacy name and a state license.
- Ask whether the ingredient appears on FDA’s 503A bulks list. If the answer is yes, ask for the entry. Six substances are on the current list, and none of them is BPC-157, TB-500, CJC-1295, ipamorelin, sermorelin or GHK-Cu.
- Ask for a published human trial of that exact compound, in that exact form, rather than a rodent study or a forum chart.
- Ask for the total recurring cost in writing, including visits, lab work, shipping and any membership that renews without a purchase.
Our peptide clinic directory lists providers state by state with those questions attached, and our regulatory tracker follows the compound-by-compound status of what regulators are actively reviewing. The tracker answers the question the videos answer with confidence, and it answers it with citations.
Frequently asked questions
What is a peptide, in plain language?
A peptide is a short chain of amino acids, the same building blocks that make up proteins. Insulin is a peptide 51 amino acids long and GLP-1 is a peptide hormone. The term describes chemistry, not a treatment benefit or a safety record.
Are the peptides sold online FDA-approved?
The compounds sold as BPC-157, TB-500, CJC-1295, ipamorelin, sermorelin, KPV, semax, selank and GHK-Cu are not components of FDA-approved drugs and do not appear on the 503A bulks list, which the FDA stated in a warning letter to Tailor Made Compounding in April 2020. Compounded versions are not FDA-approved products, and the pharmacy that makes one is not an approved manufacturer.
Does “research use only” on a peptide vial mean anything legally?
The FDA rejected that defense in a December 10, 2024 warning letter to Prime Vitality, doing business as Prime Peptides. The agency found the label meaningless because the seller’s own website described what the products do in the human body, which made them drugs for human use and therefore unapproved new drugs.
What has the FDA said about BPC-157 specifically?
Its safety page states that compounded BPC-157 may pose immunogenicity and impurity risks, that the agency has no or only limited safety information for the proposed routes of administration, and that it lacks sufficient information to know whether the drug would cause harm in humans.
Which peptides does the FDA list as raising significant safety risks?
The current category 2 list under section 503A names cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10 and quinacrine hydrochloride for intrauterine use. A separate group was previously placed in category 2 and then withdrawn by the nominators, and its safety write-ups remain public. That group includes BPC-157, CJC-1295, ipamorelin acetate, thymosin beta-4 fragment, KPV, epitalon, semax, selank, AOD-9604, PEG-MGF, DSIP and GHK-Cu for injection.
Is GHK-Cu legal to compound yet?
It is under evaluation, not approved. GHK-Cu for non-injectable routes sits in FDA category 1, and the agency has announced it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about adding GHK-Cu to the 503A bulks list. Until a final rule adds it, the injectable form is not eligible under the compounding exemptions.
Two disclosures belong on the record. This page is a directory, not a clinic, and we do not sell peptides. Directory inclusion is not a treatment recommendation, and nothing here is a dosing instruction or a substitute for a licensed clinician’s assessment.
Sources: FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (categories, updated May 14, 2026), FDA warning letter to Prime Vitality, Inc. dba Prime Peptides, December 10, 2024, FDA warning letter to Tailor Made Compounding LLC, April 1, 2020, FDA, July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee.
We followed one half of that list further, compound by compound, in peptides side effects: 17 withdrawn, the warnings kept.